Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12376684 | 0.85 | MMP3 (0.39) | KMT2AMEN1FAAHMAPK1ALDH1A1 | |
| SCHEMBL26422098 | 0.79 | GAA (0.34) | KMT2AALDH1A1LMNAHTTKDM4E | |
| SCHEMBL13565764 | 0.77 | KMT2A (0.40) | KMT2AMEN1FAAHMAPK1ALDH1A1 | |
| SCHEMBL12376692 | 0.77 | KMT2A (0.40) | KMT2AMEN1FAAHMAPK1ALDH1A1 | |
| SCHEMBL25817666 | 0.76 | HIF1A (0.43) | LMNAHTT | |
| SCHEMBL13342376 | 0.75 | LMNA (0.65) | KMT2AMEN1ALDH1A1LMNACYP2C19 | |
| SCHEMBL7724917 | 0.74 | ALDH1A1 (0.50) | KMT2AMEN1FAAHMAPK1ALDH1A1 | |
| SCHEMBL14393899 | 0.74 | CYP2C19 (0.39) | KMT2AMEN1ALDH1A1CYP2C19GAA | |
| SCHEMBL22035847 | 0.72 | MEN1 (0.44) | KMT2AMEN1FAAHMAPK1ALDH1A1 | |
| SCHEMBL12967173 | 0.72 | ALDH1A1 (0.38) | ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120251497-A1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS, INC. | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120251497-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, LIPC, HCCS | KMT2A 4092/4885MEN1 4815/4885FAAH 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.